Business
Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that data on two of its proprietary glaucoma and dry eye technologies, the OMNI® Surgical System and the TearCare® System, will be presented at this year’s ASCRS Annual Meeting held in Washington, DC. “
About this update from Sight Sciences, Inc.
[{"type":"image","alt":"Sight Sciences, Inc.","displaySize":"","headline":null,"caption":"Sight Sciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/75f822c295d5666cdf692b6ef7429971"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2ddEXb7XDetW_j_3SF01ZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0OA--/https://media.zenfs.com/en/globenewswire.com/75f822c295d5666cdf692b6ef7429971","width":300,"height":106}},"lazy":false},{"type":"text","content":"MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that data on two of its proprietary glaucoma and dry eye technologies, the OMNI® Surgical System and the TearCare® System, will be presented at this year’s ASCRS Annual Meeting held in Washington, DC.","length":503,"tagName":"p"},{"type":"text","content":"“We look forward to highlighting new clinical data on our interventional technologies at the 2026 ASCRS meeting, the largest annual meeting for anterior segment surgeons,” said Paul Badawi, CEO and co-founder of Sight Sciences. “The data reinforce the durability and versatility of OMNI by demonstrating significant reductions in long-term diurnal IOP fluctuations regardless of lens status, while new TearCare results underscore the strength of our technology and showcase its clinical benefit to demonstrate early and sustained superiority of TearCare over Restasis in achieving a clinically relevant change in tear film stability. Collectively, the strength and growing depth of our clinical portfolio supports broader eyecare provider adoption and differentiated positioning in our core markets. We are thankful to all our clinical collaborators for their work demonstrating and sharing the benefits of our interventional technologies.”","length":940,"tagName":"p"},{"type":"text","content":"TearCare System Oral and Poster Presentations: ","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Outcomes for Localized Heat Therapy (LHT) or Cyclosporine in Dry Eye Disease (DED) Signs and Symptoms by Baseline Severity, Saturday, April 11 at 3:45 PM ET,...